Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)
Conditions
Interventions
Luveltamab tazevibulin
Locations
36
United States
Childrens Hospital of Alabama
Birmingham, Alabama, United States
Childrens Hospital of Los Angeles
Los Angeles, California, United States
Lucile Packard Childrens Hospital-Stanford
Palo Alto, California, United States
Children's Hospital of Colorado
Aurora, Colorado, United States
Childrens National Hospital
Washington D.C., District of Columbia, United States
Children's Hospital of Atlanta-Emory
Atlanta, Georgia, United States
Start Date
December 4, 2024
Primary Completion Date
June 1, 2025
Completion Date
June 1, 2025
Last Updated
August 24, 2025
NCT07500441
NCT05768932
NCT05756777
NCT07451912
NCT06660368
NCT05143996
Lead Sponsor
Sutro Biopharma, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions